Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. Dimairo M, et al. Among authors: hamasaki t. Trials. 2020 Jun 17;21(1):528. doi: 10.1186/s13063-020-04334-x. Trials. 2020. PMID: 32546273 Free PMC article.
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design.
Dimairo M, Coates E, Pallmann P, Todd S, Julious SA, Jaki T, Wason J, Mander AP, Weir CJ, Koenig F, Walton MK, Biggs K, Nicholl J, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG. Dimairo M, et al. Among authors: hamasaki t. BMC Med. 2018 Nov 16;16(1):210. doi: 10.1186/s12916-018-1196-2. BMC Med. 2018. PMID: 30442137 Free PMC article.
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. Dimairo M, et al. Among authors: hamasaki t. BMJ. 2020 Jun 17;369:m115. doi: 10.1136/bmj.m115. BMJ. 2020. PMID: 32554564 Free PMC article.
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Turner NA, et al. Among authors: hamasaki t. Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. Trials. 2022. PMID: 35578360 Free PMC article.
Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
Nakao K, Noguchi T, Asaumi Y, Morita Y, Kanaya T, Fujino M, Hosoda H, Yoneda S, Kawakami S, Nagai T, Nishihira K, Nakashima T, Kumasaka R, Arakawa T, Otsuka F, Nakanishi M, Kataoka Y, Tahara Y, Goto Y, Yamamoto H, Hamasaki T, Yasuda S. Nakao K, et al. Among authors: hamasaki t. Trials. 2018 Jan 8;19(1):12. doi: 10.1186/s13063-017-2353-1. Trials. 2018. PMID: 29310688 Free PMC article.
645 results